Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Objective
To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population).
Persp...
Alternative Titles
Full title
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6021464
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6021464
Other Identifiers
ISSN
1170-7690
E-ISSN
1179-2027
DOI
10.1007/s40273-018-0675-9
